clinical development – Page 14 – Communicable Diseases Research

COVID-19, Companion Animals, Comparative Medicine, and One Health

Veterinary Science

Published on 2020-08-142022-11-01
Journal: Frontiers in Veterinary Science [Category] COVID-19,

Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review

Cardiovascular Medicine

Published on 2020-08-112022-10-31
Journal: Frontiers in Cardiovascular Medicine [Category] COVID-19,

[키워드] 2019 novel coronavirus ACE2 ACE2 mRNA acute respiratory syndrome Angiotensin 1-7 bind cardiovascular damage cardiovascular diseases cardiovascular system caused cells clinical development clinical manifestation coronavirus COVID-19 develop disease downregulation drug epithelial cells expressed expression Heart damage host cell surface hydroxychloroquine/chloroquine interfere Local losartan lung lung alveolar mechanism modulate mRNA expression narrative pandemic Patient patients with COVID-19 pulmonary damage RAS RAS inhibitor RAS inhibitors reduced renin-angiotensin system respiratory symptoms responsible review SARS-CoV-2 System therapy Transmission umifenovir virulence virus
[DOI] 10.3389/fcvm.2020.00143 PMC 바로가기 [Article Type] Cardiovascular Medicine

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial

중환자실에 입원한 COVID-19 환자의 정맥 주사 멜라토닌의 효능과 안전성을 조사하기 위한 2상, 단일 센터, 이중 맹검, 무작위 위약 대조 시험(MelCOVID 연구): 연구 프로토콜의 구조화된 요약 무작위 대조 시험을 위해

Letter

Published on 2020-08-052022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 6 hours Acute hypoxemic respiratory failure addition Admission Adult patients adverse effect adverse event adverse events age allocation anticipated Autoimmune disease Biochemical parameters blinded Blinding blood gas blood gas analysis body weight C-reactive protein Caregivers carried chronic Chronic kidney disease clinical condition clinical development commercialization comparator compatible symptom compatible symptoms Complete completion computer conducted Confirmed Consent Control control arm control group COVID-19 COVID-19-associated thromboembolic phenomena Critically ill D-dimer daily dose Date determined by disease dissemination double-blind Efficacy and safety element enzyme EU Clinical Trial evaluate evaluate the effect exclusion criteria expected experimental arm experimental group failing organ failing organs family member ferritin Frequency gas analysis GFR greater hematologic Hemodialysis hypoxemic Hypoxemic respiratory failure ICU ICU admission impairment Inclusion inclusion criteria increase in inflammatory state Informed institutional protocols intensive care intensive care unit interleukin interleukin-6 intravenous Kidney disease legal guardian less liver enzymes maximum mechanical ventilation medical illness melatonin Mortality multi-organ failure normal range number objective Organ failure outcome parameters participant Patient patient condition patients with COVID-19 per day performed phase physician Placebo placebo-controlled randomized trial plasma Plasma levels positive RT-PCR Pregnancy pregnancy test Prevent procalcitonin Program protocol provided randomization randomization sequence Randomized Randomized controlled trial randomized placebo-controlled trial receive recruited recruitment reduced reduction Respiratory failure Sample size SARS-COV-2 infection SAS version 9.4 SAS version 9.4 statistical software secondary Secondary objectives Sequential Organ Failure Assessment severity single center single-center SOFA Spain Stage Standard-of-care statistical status study drug study group study groups study period Study protocol systemic inflammatory response Terminal surgical thromboembolic Treatment Trial Trial registration two-arm parallel Ventilator-free days website with COVID-19 worsening written Informed Consent
[DOI] 10.1186/s13063-020-04632-4 PMC 바로가기 [Article Type] Letter

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

후보 중동 호흡기 증후군 코로나바이러스 바이러스 매개 백신의 안전성 및 면역원성: 용량 증량, 공개, 비무작위, 비통제, 1상 시험

Article

Published on 2020-07-012022-08-13
Journal: The Lancet. Infectious Diseases [Category] 임상,

[키워드] absence adverse event AID All participant All participants antibody Antigen Arabian Peninsula assigned baseline cellular cellular and humoral immunogenicity cellular response ChAdOx1 ChAdOx1 MERS clinical clinical development clinical trial coronavirus Department described dose dose-escalation doses effective elicit ELISA enzyme enzyme-linked immunospot expressing finding FIVE Follow-up follow-up period full-length full-length spike surface glycoprotein funding healthy hepatitis B hepatitis B surface antigen hepatitis C hepatitis C antibodies hepatitis C antibody High-dose high-dose group HIV antibodies humans humoral humoral immunogenicity IgG immunogenicity ImmunoSpot Infection interferon interferon-γ-linked enzyme-linked immunospot intermediate-dose group Intervention Intramuscular injection low-dose Medicine MERS MERS-CoV MERS-CoV spike antigen Middle East Middle East respiratory syndrome Coronavirus Mild mild in severity moderate neutralisation neutralisation assay Neutralising Antibodies nine Occurrence Open-label Oxford participant Phase 1 phase 1 trial pre-vaccination test pre-vaccination tests pregnancy test progression proportion Pseudotyped virus public health Registered Relative risk reported resolved respiratory respiratory syndrome coronavirus response risk Safe Safety Saudi Arabia Serious Adverse Event Serious Adverse Events severe adverse event significant increase significantly higher simian adenovirus-vectored vaccine single dose Support surface antigen Surface glycoprotein T-cell tested Tolerability trials tropical medicine urinary pregnancy test vaccination vectored vaccine Viral viral particle Viral particles virus neutralising assay virus neutralising assays was done women
[DOI] 10.1016/S1473-3099(20)30160-2 PMC 바로가기 [Article Type] Article

A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

뮤신-1 감소 화합물에 대한 고함량 검사를 통해 포스타마티닙이 COVID-19 대유행 기간 동안 급성 폐 손상에 대한 신속한 용도 변경을 위한 후보로 확인됨

Article

Published on 2020-06-302022-09-11
Journal: bioRxiv [Category] 비임상,

[키워드] acute lung injury apical surface approved ARDS arising biochemical marker breath candidate Cell cell surface clinical development clinical outcomes clinical trial clinical trials Compound content COVID-19 pandemic distress drug drug candidate Drug repurposing Efficacy elevated epithelial cells expressed fostamatinib identify Immune thrombocytopenia inhibitor Lung disease lung epithelial cell Lung epithelial cells Lung injury membrane-bound mouse model MUC1 mucin mucosal pandemic pandemic spread Patient patients with COVID-19 predict promoted Protein provide R788 Rapid rationale reduce reduced repurposing required respiratory distress Respiratory distress syndrome reveal SARS-CoV-2 SARS-COV-2 infection Screen spleen Spread Stage standing up SYK syndrome the cell thrombocytopenia Treatment tyrosine
[DOI] 10.1101/2020.06.30.180380 PMC 바로가기 [Article Type] Article

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19

Review

Published on 2020-06-282022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] Admission advanced respiratory support approach approved Canagliflozin cardiovascular cardiovascular disease Chronic kidney disease clinical development clinical trial Clinical use Coronavirus disease 2019 COVID-19 COVID-19 patient Cytokine storm Dapagliflozin diabetes Diabetic effort Empagliflozin Factor faster Glucose include Inflammatory inhibitor kidney Ligand lung Mortality organ organ function organ support outcome pandemic potential benefit preclinical data PROTECT protection receiving renal replacing Repurposed drug Respiratory failure risk severe COVID-19 SGLT2 shown sodium Spread Support Therapies therapy thought thromboembolic complication Vaccine viral replication
[DOI] 10.3390/jcm9072030 PMC 바로가기 [Article Type] Review

COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment

Review

Published on 2020-06-242022-10-30
Journal: Journal of Fungi [Category] COVID-19,

[키워드] Activation acute respiratory distress antiviral immunity ARDS aspergillosis Aspergillus Autopsy Bronchoalveolar lavage fluid caused challenges clinical development Co-infection contribute Coronavirus disease-19 COVID-19 COVID-19 patient Culture danger-associated molecular pattern diagnostic test disease disease transmission drug drug–drug interaction Effect epithelial European Confederation of Medical Mycology Expert statement favor fungal Host ICU immune response Inflammatory inflammatory disease Influenza Like Novel coronavirus Pathogenesis pathway Patient performed pharmacokinetic Prevalence profiles pulmonary renal required resulting risk risk factor Risk factors SARS CoV-2 SARS-CoV-2 severe COVID-19 superinfection syndrome Treatment urgency
[DOI] 10.3390/jof6020091 PMC 바로가기 [Article Type] Review

Emerging Prevention and Treatment Strategies to Control COVID-19

Review

Published on 2020-06-232022-10-28
Journal: Pathogens [Category] COVID-19,

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques

Research Article

Published on 2020-06-102022-11-01
Journal: Science Advances [Category] Coronavirus,

Potential anti‐SARS‐CoV‐2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease

Research Article

Published on 2020-05-292022-10-31
Journal: FEBS Open Bio [Category] COVID-19, MERS, SARS,